Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
17.5M
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
5.14M
-
Shares change
-
+5.14M
-
Total reported value, excl. options
-
$24.6M
-
Value change
-
+$24.6M
-
Number of buys
-
19
-
Price
-
$4.77
Significant Holders of Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value (UNCY) as of Q2 2025
19 filings reported holding UNCY - Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value as of Q2 2025.
Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value (UNCY) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.14M shares
of 17.5M outstanding shares and own 29.32% of the company stock.
Largest 10 shareholders include Vivo Capital, LLC (1.14M shares), Octagon Capital Advisors LP (1M shares), Nantahala Capital Management, LLC (939K shares), GREAT POINT PARTNERS LLC (797K shares), VANGUARD GROUP INC (606K shares), Logos Global Management LP (474K shares), ACUTA CAPITAL PARTNERS, LLC (62.9K shares), GEODE CAPITAL MANAGEMENT, LLC (58.8K shares), JPMORGAN CHASE & CO (21.7K shares), and STATE STREET CORP (12.5K shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.